Xaluprine 20 mg/ml oral suspension *
Pharmacy Only: Prescription

Updated on 27 June 2022

File name

62b997aba1ecf.pdf

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to restricted prescription (C)

Updated on 27 June 2022

File name

62b9978f3866c.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect

Updated on 27 June 2022

File name

62b977863396a.pdf

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to restricted prescription (C)

Updated on 27 June 2022

File name

62b977624f5d7.pdf

Reasons for updating

  • Change to section 6 - date of revision

Updated on 24 June 2022

File name

62b56f70b99ab.pdf

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to restricted prescription (C)

Updated on 24 June 2022

File name

62b56f4bb094e.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect

Updated on 23 June 2022

File name

62b475c33b1d1.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to restricted prescription (C)

Updated on 23 June 2022

File name

62b4733b681ea.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 13 January 2022

File name

SPC_1642089595.pdf

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category:Product subject to restricted prescription (C)

Updated on 12 March 2021

File name

PIL_1615566098.pdf

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 07 February 2021

File name

PIL_1612695535.pdf

Reasons for updating

  • Change to section 6 - manufacturer

Free text change information supplied by the pharmaceutical company

Addition of Pronav Clinical Ltd. as manufacturer.

Updated on 08 June 2020

File name

Summary of Product Characteristics_1591610122.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to restricted prescription (C)

Updated on 08 June 2020

File name

Package Leaflet_1591609943.pdf

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - excipient warnings
  • Change to section 3 - how to take/use

Updated on 17 December 2019

File name

Summary of product characteristics_1576596100.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to restricted prescription (C)

Updated on 17 December 2019

File name

Package leaflet_1576596073.pdf

Reasons for updating

  • New PIL for new product